Emagneneh T, Mulugeta C, Ejigu B, Alamrew A, Hiwot A, Feleke S
Front Oncol. 2025; 14():1491840.
PMID: 39839767
PMC: 11746072.
DOI: 10.3389/fonc.2024.1491840.
Alhamlan F, Albadawi I, Al-Qahtani A, Awartani K, Obeid D, Tulbah A
Front Microbiol. 2024; 15:1489942.
PMID: 39664050
PMC: 11631898.
DOI: 10.3389/fmicb.2024.1489942.
Usman A, Bello S, Abdurrahman A, Rasheed F, Adam S, Dahiru A
Ecancermedicalscience. 2024; 18:1750.
PMID: 39421162
PMC: 11484695.
DOI: 10.3332/ecancer.2024.1750.
Alwosaibai K, Alruwaii Z, Mashhour M, Almsned F, Asraf R, Alrsheedy W
Sci Rep. 2024; 14(1):24191.
PMID: 39406772
PMC: 11480429.
DOI: 10.1038/s41598-024-74192-z.
Parapob N, Lekawanvijit S, Tongsong T, Charoenkwan K, Tantipalakorn C
Obstet Gynecol Sci. 2024; 67(6):557-564.
PMID: 39376071
PMC: 11581809.
DOI: 10.5468/ogs.24117.
A comprehensive review on the potential of coumarin and related derivatives as multi-target therapeutic agents in the management of gynecological cancers.
Seker Karatoprak G, Dumlupinar B, Celep E, Kurt Celep I, Akkol E, Sobarzo-Sanchez E
Front Pharmacol. 2024; 15:1423480.
PMID: 39364049
PMC: 11447453.
DOI: 10.3389/fphar.2024.1423480.
Pan-immune-inflammation value: a new prognostic index in epithelial ovarian cancer.
Liao W, Li J, Feng W, Kong W, Shen Y, Chen Z
BMC Cancer. 2024; 24(1):1052.
PMID: 39187781
PMC: 11345988.
DOI: 10.1186/s12885-024-12809-2.
Global burden and trends in pre- and post-menopausal gynecological cancer from 1990 to 2019, with projections to 2040: a cross-sectional study.
Liang Y, Dai X, Chen J, Zeng X, Qing X, Huang J
Int J Surg. 2024; 111(1):891-903.
PMID: 39093825
PMC: 11745647.
DOI: 10.1097/JS9.0000000000001956.
Predictive modeling and web-based tool for cervical cancer risk assessment: A comparative study of machine learning models.
Chauhan R, Goel A, Alankar B, Kaur H
MethodsX. 2024; 12:102653.
PMID: 38524310
PMC: 10957413.
DOI: 10.1016/j.mex.2024.102653.
Phenome-wide association study of ovarian cancer identifies common comorbidities and reveals shared genetics with complex diseases and biomarkers.
Mulugeta A, Lumsden A, Madakkatel I, Stacey D, Lee S, Maenpaa J
Cancer Med. 2024; 13(4):e7051.
PMID: 38457211
PMC: 10923028.
DOI: 10.1002/cam4.7051.
Developing an evaluation indicators of health literacy for cervical cancer among Chinese women: a modified Delphi method study.
He C, Pei C, Ma J
BMC Cancer. 2023; 23(1):863.
PMID: 37700262
PMC: 10498636.
DOI: 10.1186/s12885-023-11208-3.
MALDI-TOF MS Analysis of Serum Peptidome Patterns in Cervical Cancer.
Rungkamoltip P, Roytrakul S, Navakanitworakul R
Biomedicines. 2023; 11(8).
PMID: 37626823
PMC: 10452062.
DOI: 10.3390/biomedicines11082327.
Profile of gynecological cancers in a tertiary hospital, Eastern Nigeria.
Nzeribe E, Ododo N, Eteike P
Pan Afr Med J. 2023; 44:139.
PMID: 37333784
PMC: 10276339.
DOI: 10.11604/pamj.2023.44.139.39034.
Resveratrol Enhances Cytotoxic Effects of Cisplatin by Inducing Cell Cycle Arrest and Apoptosis in Ovarian Adenocarcinoma SKOV-3 Cells through Activating the p38 MAPK and Suppressing AKT.
Hankittichai P, Thaklaewphan P, Wikan N, Ruttanapattanakul J, Potikanond S, Smith D
Pharmaceuticals (Basel). 2023; 16(5).
PMID: 37242538
PMC: 10220637.
DOI: 10.3390/ph16050755.
The association between TIPARP gene polymorphisms rs2665390 and ovarian cancer susceptibility.
Vahidi M, Houshmand M, Banoei M, Heidari F
Gynecol Oncol Rep. 2023; 47:101175.
PMID: 37091214
PMC: 10113771.
DOI: 10.1016/j.gore.2023.101175.
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.
OMahony D, Ramus S, Southey M, Meagher N, Hadjisavvas A, John E
Br J Cancer. 2023; 128(12):2283-2294.
PMID: 37076566
PMC: 10241792.
DOI: 10.1038/s41416-023-02263-5.
TROP-2 is widely expressed in vulvar squamous cell carcinoma and represents a potential new therapeutic target.
Condic M, Egger E, Klumper N, Kristiansen G, Mustea A, Thiesler T
J Cancer Res Clin Oncol. 2023; 149(11):8235-8241.
PMID: 37067548
PMC: 10374825.
DOI: 10.1007/s00432-023-04761-8.
Nomograms for predicting overall survival and cancer-specific survival in elderly patients with epithelial ovarian cancer.
Cheng H, Xu J, Kang X, Wu C, Tang X, Chen M
J Ovarian Res. 2023; 16(1):75.
PMID: 37059991
PMC: 10103408.
DOI: 10.1186/s13048-023-01144-y.
Exosomes as crucial emerging tools for intercellular communication with therapeutic potential in ovarian cancer.
Malgundkar S, Tamimi Y
Future Sci OA. 2023; 9(1):FSO833.
PMID: 37006229
PMC: 10051132.
DOI: 10.2144/fsoa-2022-0032.
Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Havasi A, Cainap S, Havasi A, Cainap C
Medicina (Kaunas). 2023; 59(3).
PMID: 36984544
PMC: 10057458.
DOI: 10.3390/medicina59030544.